Sara Bonstein Sells 2,404 Shares of Insmed (NASDAQ:INSM) Stock

Posted by on Jun 7th, 2026

Insmed, Inc. (NASDAQ:INSM – Get Free Report) CFO Sara Bonstein sold 2,404 shares of the stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total transaction of $245,857.08. Following the completion of the sale, the chief financial officer directly owned 69,082 shares of the company’s stock, valued at approximately $7,065,016.14. This trade represents a 3.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Insmed Stock Performance

Shares of NASDAQ INSM opened at $94.22 on Friday. The firm has a fifty day moving average price of $130.45 and a 200-day moving average price of $154.95. The company has a debt-to-equity ratio of 0.80, a current ratio of 4.47 and a quick ratio of 4.10. The stock has a market cap of $20.42 billion, a PE ratio of -16.39 and a beta of 0.79. Insmed, Inc. has a 1 year low of $70.57 and a 1 year high of $212.75.

Insmed (NASDAQ:INSM – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.14. The firm had revenue of $305.96 million during the quarter, compared to analysts’ expectations of $300.81 million. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. The company’s revenue for the quarter was up 229.7% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.42) earnings per share. Equities analysts anticipate that Insmed, Inc. will post -2.56 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on INSM. Royal Bank Of Canada reduced their price objective on shares of Insmed from $205.00 to $195.00 and set an “outperform” rating for the company in a research note on Friday. Raymond James Financial began coverage on shares of Insmed in a research note on Friday, April 10th. They issued an “outperform” rating and a $200.00 price objective for the company. Jefferies Financial Group initiated coverage on shares of Insmed in a research note on Monday, March 16th. They issued a “buy” rating and a $228.00 price objective for the company. Roth Mkm reaffirmed a “buy” rating and set a $212.00 target price on shares of Insmed in a research note on Friday, April 17th. Finally, Wells Fargo & Company cut their target price on shares of Insmed from $177.00 to $160.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $210.50.

Check Out Our Latest Stock Report on Insmed

Hedge Funds Weigh In On Insmed

Several institutional investors have recently bought and sold shares of the stock. CIBC Private Wealth Group LLC grew its stake in Insmed by 42.1% during the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 53 shares in the last quarter. Kingsview Wealth Management LLC grew its stake in Insmed by 2.7% during the third quarter. Kingsview Wealth Management LLC now owns 2,321 shares of the biopharmaceutical company’s stock valued at $334,000 after acquiring an additional 60 shares in the last quarter. Choreo LLC grew its stake in Insmed by 2.9% during the third quarter. Choreo LLC now owns 2,319 shares of the biopharmaceutical company’s stock valued at $334,000 after acquiring an additional 65 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in Insmed by 10.2% during the fourth quarter. EverSource Wealth Advisors LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $130,000 after acquiring an additional 69 shares in the last quarter. Finally, ORG Partners LLC grew its stake in Insmed by 12.7% during the fourth quarter. ORG Partners LLC now owns 657 shares of the biopharmaceutical company’s stock valued at $114,000 after acquiring an additional 74 shares in the last quarter.

About Insmed

(Get Free Report)

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.

Read More

Insider Buying and Selling by Quarter for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.